123I-FP-CIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component

Frontiers in Systems Neuroscience

Volumn 9, Issue July, 2015, Pages

  Garriga, Marina ^a   Milà, Marta ^a   Mir, Manzoor ^b   Al Baradie, Raid ^b   Huertas, Sonia ^a   Castejon, Cesar ^a   Casas, Laura ^a   Badenes, Dolors ^a   Giménez, Nuria ^c   Font, M Angels ^c   Gonzalez, Jose M ^a   Ysamat, Maria ^a   Aguilar, Miguel ^a   Slevin, Mark ^d   Krupinski, Jerzy ^a,d  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b MAJMAAH UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF BARCELONA   (Spain)

^d MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

123I FP CIT SPECT; Dementia; Framingham risk score; Mild cognitive impairment

Indexed keywords

IOFLUPANE I 123;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD EXAMINATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DOPAMINERGIC ACTIVITY; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84937877439     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2015.00099     Document Type: Article

References (54)

1. Albanese, E., Banerjee, S., Dhanasiri, S., Fernandez, J. L., Ferri, C., Knapp, M., et al. (2007). A Report to the Alzheimer's Society on the Prevalence and Ecnonomic Cost of Dementia in the UK. Dementia UK: King's College London and London School of Economics.
2. Bouwmans, A. E., Vlaar, A. M., Mess, W. H., Kessels, A., and Weber, W. E. (2013). Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. BMJ Open3:e002613. doi: 10.1136/bmjopen-2013-002613
3. Breteler, M. M. (2000). Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging 21, 153-160. doi: 10.1016/S0197-4580(99)00110-4
4. Brun, A., and Englund, E. (1986). Brain changes in dementia of Alzheimer's type relevant to new imaging diagnostic methods. Prog. Neuropsychopharmacol. Biol. Psychiatry 10, 297-308. doi: 10.1016/0278-5846(86)90009-6
5. Carmichael, O., Schwarz, C., Drucker, D., Fletcher, E., Harvey, D., Beckett, L., et al. (2010). Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch. Neurol. 67, 1370-1378. doi: 10.1001/archneurol.2010.284
6. Chen, Y. J., Deutsch, G., Satya, R., Liu, H. G., and Mountz, J. M. (2013). A semi-quantitative method for correlating brain disease groups with normal controls using SPECT: Alzheimer's disease versus vascular dementia. Comput. Med. Imaging Graph.37, 40-47. doi: 10.1016/j.compmedimag.2012.11.001
7. Chui, H. C., and Ramirez-Gomez, L. (2015). Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res. Ther. 7:21. doi: 10.1186/s13195-015-0104-7
8. Cummings, J. L., Henchcliffe, C., Schaier, S., Simuni, T., Waxman, A., and Kemp, P. (2011). The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 134(Pt. 11), 3146-3166. doi: 10.1093/brain/awr177
9. D'Agostino, R. B. Sr., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., et al. (2008). General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117, 743-753. doi: 10.1161/CIRCULATIONAHA.107.699579
10. DeCarli, C., Murphy, D. G., Tranh, M., Grady, C. L., Haxby, J. V., Gillette, J. A., et al. (1995). The effect of white matter hyperintensity volume on brain structure, cognitive performance and cerebral metabolism of glucose in 51 healthy adults. Neurology 45, 2077-2084. doi: 10.1212/wnl.45.11.2077
11. de Souza, L. C., Lehéricy, S., Dubois, B., Stella, F., and Sarazin, M. (2012). Neuroimaging in dementias. Curr. Opin. Psychiatry 25, 473-479. doi: 10.1097/YCO.0b013e328357b9ab
12. Eckerström, C., Olsson, E., Klasson, N., Bjerke, M., Göthlin, M., Jonsson, M., et al. (2011). High white matter lesion load is associated with hippocampal atrophy in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 31, 132-138. doi: 10.1159/000323014
13. Elias, M. F., Sullivan, L. M., D'Agostino, R. B., Elias, P. K., Beiser, A., Au, R., et al. (2004). Framingham stroke risk profile and lowered cognitive performance. Stroke35, 404-409. doi: 10.1161/01.str.0000103141.82869.77
14. Erixon-Lindroth, N., Farde, L., Wahlin, T. B., Sovago, J., Halldin, C., and Bäckman, L. (2005). The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res. 138, 1-12. doi: 10.1016/j.pscychresns.2004.09.005
15. Eshuis, S. A., Maguire, R. P., Leenders, K. L., Jonkman, S., and Jager, P. L. (2006). Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur. J. Nucl. Med. Mol. Imaging 33, 200-209. doi: 10.1007/s00259-005-1904-y
16. Fischer, V. W., Siddiqi, A., and Yusufaly, Y. (1990). Altered angioarchitecture in selected areas of brains with Alzheimer's disease. Acta Neuropathol. 79, 672-679. doi: 10.1007/bf00294246
17. Garcia-Alloza, M., Gregory, J., Kuchibhotla, K. V., Fine, S., Wei, Y., Ayata, C., et al. (2011). Cerebrovascular lesions induce transient β-amyloid deposition. Brain 134(Pt 12), 3697-3707. doi: 10.1093/brain/awr300
18. García Vicente, A. M., Vaamonde Cano, J., Soriano Castrejón, A., Martínez Delgado, C., Talavera Rubio, P., Poblete García, V. M., et al. (2005). Utility of 123-I ioflupane SPECT in the assessment of patients with Parkinsonian syndrome and cerebral vasculopathy. Rev. Esp. Med. Nucl. 24, 392-403. doi: 10.1016/S0212-6982(05)74184-7
19. Garibotto, V., Montandon, M. L., Viaud, C. T., Allaoua, M., Assal, F., Burkhard, P. R., et al. (2013). Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin. Nucl. Med. 38, e112-e117. doi: 10.1097/rlu.0b013e318279b991
20. Gerschlager, W., Bencsits, G., Pirker, W., Bloem, B. R., Asenbaum, S., Prayer, D., et al. (2002). 123Ibeta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov. Disord. 17, 518-523. doi: 10.1002/mds.10092
21. Herholz, K. (2012). Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. Biomark. Med. 6, 431-439. doi: 10.2217/bmm.12.51
22. Iadecola, C. (2010). The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 120, 287-296. doi: 10.1007/s00401-010-0718-6
23. Iadecola, C., and Gorelick, P. B. (2003). Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 34, 335-337. doi: 10.1161/01.str.0000054050.51530.76
24. Jabłoński, M., Maciejewski, R., Januszewski, S., Ułamek, M., and Pluta, R. (2011). One year follow up in ischemic brain injury and the role of Alzheimer factors. Physiol. Res.60(Suppl. 1), S113-S119.
25. Jeerakathil, T., Wolf, P. A., Beiser, A., Massaro, J., Seshadri, S., D'Agostino, R. B., et al. (2004). Stroke risk profile predicts white matter hyperintensity volume: the Framingham study. Stroke 35, 1857-1861. doi: 10.1161/01.str.0000135226.53499.85
26. Kalaria, R. N. (2012). Risk factors and neurodegenerative mechanisms in stroke related dementia. Panminerva Med. 54, 139-148.
27. Kemp, P. M., and Holmes, C. (2007). Imaging in dementia with Lewy bodies: a review.Nucl. Med. Commun. 28, 511-519. Review. doi: 10.1097/mnm.0b013e3281e20a12
28. Kim, H. A., Miller, A. A., Drummond, G. R., Thrift, A. G., Arumugam, T. V., Phan, T. G., et al. (2012). Vascular cognitive impairment and Alzheimer's disease: role of cerebral hypoperfusion and oxidative stress. Naunyn Schmiedebergs Arch. Pharmacol. 385, 953-959. doi: 10.1007/s00210-012-0790-7
29. Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., et al. (1997). The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann. N Y Acad. Sci. 826, 422-427. doi: 10.1111/j.1749-6632.1997.tb48496.x
30. Lorberboym, M., Djaldetti, R., Melamed, E., Sadeh, M., and Lampl, Y. (2004). 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J. Nucl. Med. 45, 1688-1693.
31. Marchesi, V. T. (2011). Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J. 25, 5-13. doi: 10.1096/fj.11-0102ufm
32. Marshall, V., and Grosset, D. (2003). Role of dopamine transporter imaging in routine clinical practice. Mov. Disord. 18, 1415-1423. doi: 10.1002/mds.10592
33. McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., et al. (2005). Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65, 1863-1872. doi: 10.1212/01.wnl.0000187889.17253.b1
34. Mills, S., Cain, J., Purandare, N., and Jackson, A. (2007). Biomarkers of cerebrovascular disease in dementia. Br. J. Radiol. 80 Spec. No. 2, S128-S145. doi: 10.1259/bjr/79217686
35. Niwa, K., Kazama, K., Younkin, L., Younkin, S. G., Carlson, G. A., and Iadecola, C. (2002). Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart Circ. Physiol. 283, H315-H323. doi: 10.1152/ajpheart.00022.2002
36. O'Brien, J. T., McKeith, I. G., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., et al. (2009). Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br. J. Psychiatry 194, 34-39. doi: 10.1192/bjp.bp.108.052050
37. Ott, A., Breteler, M. M., de Bruyne, M. C., van Harskamp, F., Grobbee, D. E., and Hofman, A. (1997). Atrial fibrillation and dementia in a population-based study. The Rotterdam study. Stroke 28, 316-321. doi: 10.1161/01.str.28.2.316
38. Pendlebury, S. T., and Rothwell, P. M. (2009). Prevalence, incidence and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 8, 1006-1018. doi: 10.1016/s1474-4422(09)70236-4
39. Pluta, R., Furmaga-Jabłońska, W., Maciejewski, R., Ułamek-Kozioł, M., and Jabłoński, M. (2013). Brain ischemia activates β- and γ-secretase cleavage of amyloid precursor protein: significance in sporadic Alzheimer's disease. Mol. Neurobiol. 47, 425-434. doi: 10.1007/s12035-012-8360-z
40. Purnell, C., Gao, S., Callahan, C. M., and Hendrie, H. C. (2009). Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature.Alzheimer Dis. Assoc. Disord. 23, 1-10. doi: 10.1097/WAD.0b013e318187541c
41. Scheltens, P., Barkhof, F., Valk, J., Algra, P. R., van der Hoop, R. G., Nauta, J., et al. (1992). White matter lesions on magnetic resonance imaging in clinically diagnosed Alzheimer's disease. Evidence for heterogeneity. Brain 115(Pt. 3), 735-748. doi: 10.1093/brain/115.3.735
42. Skoog, I., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L. A., Nilsson, L., et al. (1996). 15-year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145. doi: 10.1016/s0140-6736(96)90608-x
43. Sörös, P., Whitehead, S., Spence, J. D., and Hachinski, V. (2013). Antihypertensive treatment can prevent stroke and cognitive decline. Nat. Rev. Neurol. 9, 174-178. doi: 10.1038/nrneurol.2012.255
44. Tanimukai, H., Imaizumi, K., Kudo, T., Katayama, T., Tsuda, M., Takagi, T., et al. (1998). Alzheimer-associated presenilin-1 gene is induced in gerbil hippocampus after transient ischemia. Brain Res. Mol. Brain Res. 54, 212-218. doi: 10.1016/s0169-328x(97)00337-9
45. Tatemichi, T. K., Paik, M., Bagiella, E., Desmond, D. W., Stern, Y., Sano, M., et al. (1994). Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 44, 1885-1891. doi: 10.1212/wnl.44.10.1885
46. Tolosa, E., Borght, T. V., Moreno, E., and DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. (2007). Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov. Disord. 22, 2346-2351. doi: 10.1002/mds.21710
47. Vanitallie, T. B. (2013). Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention. Metabolism 62(Suppl. 1), S30-S33. doi: 10.1016/j.metabol.2012.08.024
48. Varrone, A., and Halldin, C. (2010). Molecular imaging of the dopamine transporter. J. Nucl. Med. 51, 1331-1334. doi: 10.2967/jnumed.109.065656
49. Visser, P. J., Wolf, H., Frisoni, G., and Gertz, H. J. (2012). Disclosure of Alzheimer's disease biomarker status in subjects with mild cognitive impairment. Biomark. Med. 6, 365-368. doi: 10.2217/bmm.12.58
50. Wahlund, L. O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögre, M., et al. (2001). A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32, 1318-1322. doi: 10.1161/01.STR.32.6.1318
51. Weng, Y. H., Yen, T. C., Chen, M. C., Kao, P. F., Tzen, K. Y., Chen, R. S., et al. (2004). Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J. Nucl. Med. 45, 393-401.
52. Wimo, A., Jönsson, L., Bond, J., Prince, M., Winblad, B., and Alzheimer Disease International. (2013). The worldwide economic impact of dementia 2010. Alzheimers Dement. 9, 1-11.e3. doi: 10.1016/j.jalz.2012.11.006
53. Wolf, P. A., D'Agostino, R. B., Belanger, A. J., and Kannel, W. B. (1991). Probability of stroke: a risk profile from the Framingham study. Stroke 22, 312-318. doi: 10.1161/01.str.22.3.312
54. Zijlmans, J., Evans, A., Fontes, F., Katzenschlager, R., Gacinovic, S., Lees, A. J., et al. (2007). [123I]FP-spect study in vascular Parkinsonism and Parkinson's disease. Mov. Disord. 2, 1278-1285. doi: 10.1002/mds.21479